6,479
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Perispinal etanercept advances as a neurotherapeutic

Pages 453-455 | Received 15 Feb 2018, Accepted 19 Apr 2018, Published online: 25 Apr 2018

References

  • Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014;25(4):453–472.
  • Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother. 2010;10(6):985–1002.
  • Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010;128(3):519–548.
  • Santello M, Volterra A. TNFalpha in synaptic function: switching gears. Trends Neurosci. 2012;35(10):638–647.
  • Faingold CL. Chapter 7: network control mechanisms: cellular inputs, neuroactive substances, and synaptic changes. In: Faingold CL, Blumenfeld H, Editors. Neuronal networks in brain function, CNS Disorders, and Therapeutics. Academic Press: London; 2014.
  • Clark IA, Vissel B, Neurologist’s A. Guide to TNF biology and to the principles behind the therapeutic removal of excess TNF in disease. Neural Plast. 2015;2015:358263.
  • Clark IA, Vissel B. Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. J Neuroinflammation. 2016;13(1):236.
  • Sainoh T, Orita S, Miyagi M, et al. Single intradiscal administration of the tumor necrosis factor-alpha inhibitor, etanercept, for patients with discogenic low back pain. Pain Med. 2016;17(1):40–45.
  • Inoue K, Tsuda M. Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nat Rev Neurosci. 2018;19(3):138–152.
  • Lei B, Dawson HN, Roulhac-Wilson B, et al. Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage. J Neuroinflammation. 2013;10:103.
  • Cheng X, Shen Y, Li R. Targeting TNF: a therapeutic strategy for Alzheimer’s disease. Drug Discov Today. 2014;19(11):1822–1827.
  • Tuttolomondo A, Pecoraro R, Pinto A. Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of evidence to date. Drug Des Devel Ther. 2014;8:2221–2239.
  • Winkelstein BA, Allen KD, Setton LA. Chapter 19: intervertebral disc herniation: pathophysiology and emerging therapies. In: Shapiro IM, Risbud MV, Editors. The intervertebral disc. Wien, Austria: Springer-Verlag; 2014.
  • Bergold PJ. Treatment of traumatic brain injury with anti-inflammatory drugs. Exp Neurol. 2016;275(Pt 3):367–380.
  • Hellewell S, Semple BD, Morganti-Kossmann MC. Therapies negating neuroinflammation after brain trauma. Brain Res. 2016;1640(Pt A):36–56.
  • Walters A, Phillips E, Zheng R, et al. Evidence for neuroinflammation in Alzheimer’s disease. Prog Neurol Psychiatry. 2016;20(September/October):25–31.
  • Clark IA. An unsound AAN Practice Advisory on poststroke etanercept. Expert Rev Neurother. 2017;17(3):215–217.
  • Dugue R, Nath M, Dugue A, et al. Roles of pro- and anti-inflammatory cytokines in traumatic brain injury and acute ischemic stroke. In: Abreu GEA, Editor. Mechanisms of neuroinflammation. InTech:London; 2017.
  • Yang Y, Zhang J, Gao Q, et al. Etanercept attenuates thermal and mechanical hyperalgesia induced by bone cancer. Exp Ther Med. 2017;13(5):2565–2569.
  • Ignatowski TA, Spengler RN, Dhandapani KM, et al. Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs. 2014;28(8):679–697.
  • Tobinick EL. Perispinal delivery of CNS drugs. CNS Drugs. 2016;30(6):469–480.
  • Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011;25(2):145–155.
  • Tobinick E, Kim NM, Reyzin G, et al. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26(12):1051–1070.
  • Tobinick E, Rodriguez-Romanacce H, Kinssies R, et al. Chapter 7 - perispinal etanercept for traumatic brain injury. In: Heidenreich KA, Editor. New therapeutics for traumatic brain injury. New York: Academic Press/Elsevier; 2017.
  • Tobinick E, Rodriguez-Romanacce H, Levine A, et al. Immediate neurological recovery following perispinal etanercept years after brain injury. Clin Drug Investig. 2014;34(5):361–366.
  • Tobinick E. Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer’s disease. Curr Alzheimer Res. 2012;9(1):99–109.
  • Tobinick E, Ignatowski TA, Spengler RN. On overcoming barriers to application of neuroinflammation research. In: Abreu GEA, Editor. Mechanisms of neuroinflammation. InTech:London; 2017.
  • Tobinick E. The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed. 2006;8(1):53.
  • Nathoo N, Caris EC, Wiener JA, et al. History of the vertebral venous plexus and the significant contributions of Breschet and Batson. Neurosurgery. 2011;69(5):1007–14; discussion 1014.
  • Tubbs RS, Demerdash A, Loukas M, et al. Intracranial connections of the vertebral venous plexus: anatomical study with application to neurosurgical and endovascular procedures at the craniocervical junction. Oper Neurosurg (Hagerstown). 2018;14(1):51–57.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.